Dear Editor,
The tumor suppressor protein p53 shares considerable structural and functional homology with its family members p63 and p73. For example, full-length human p73 (TAp73) shares 63% amino-acid identity with the DNA-binding region of p53, conserving all DNA contact residues, and 38% and 29% identity with the p53 tetramerization and transactivation domains, respectively.1 Human TAp73, or its homolog TAp63, is required for p53-mediated transcriptional activation of apoptotic genes in fibroblasts.2 However, neither TAp63 nor TAp73 are inactivated by mutations in human cancers, excluding them from being categorized as classic Knudsen-type tumor suppressors. In fact, p73 has been shown to be overexpressed in many different human cancers. This apparent contradiction in p73 activity may lie in the fact that the p73 gene produces diverse N-terminal isoforms with distinct or even opposing properties. Aside from the proapoptotic transactivation-competent TAp73 isoform, the N-terminally truncated transactivation-deficient ΔNp73 is biologically important and might play a role as an oncogene in human cancers. ΔNp73 protein is either generated from the P1 promoter by alternate Exon 3′ splicing or via an alternate P2 promoter in Intron 3. Moreover, alternate splicing at the C-terminus results in at least six different C terminal variants α−φ (of which α is the full-length version) that are thought to differ in their transcriptional potency but whose biological differences remain to be fully elucidated.3
Importantly, the ΔNp73 isoform is frequently upregulated in various human cancers, including ovarian cancer,4 breast and gynecological cancers,5 hepatocellular carcinoma,6 lung cancer,7 gastric cancer,8 thyroid cancer9 and neuroblastoma.10 Overexpression of ΔNp73 is an independent prognostic marker for reduced survival in lung cancer patients7 and in neuroblastoma patients.10 In cell-based assays, ΔNp73α displays oncogenic properties. ΔNp73α immortalizes primary mouse embryo fibroblasts (MEFs) in vitro and cooperates with oncogenic Ras in inducing MEF-derived fibrosarcomas in vivo.6, 11 Together, these results suggest that in cancer tissues, ΔNp73 overexpression plays an oncogenic role and functionally abrogates any concomitant increase in TAp73.
We were interested in further characterizing the role of ΔNp73. In addition to its inhibition of TAp73, ΔNp73 functions as a dominant-negative inhibitor of wild-type p53 and most likely of TAp63, and thus is a potent pan inhibitor of the p53 gene family.11, 12 There are no studies reported to date examining the in vivo effects of homozygous compound knockouts of individual family members. Although the loss of any one of these genes alone does not interfere with viability, it creates a significantly disrupted phenotype that is gene-specific. Deficiency of p53 leads to a strongly increased tumor susceptibility at young age, but the majority of p53-null mice survive to adulthood, indicating that p53 function is not essential for embryonic development.13 Only a small percentage of young, mainly female p53 null mice exhibit neural tube closure defects due to neuronal overgrowth with exencephaly of the midbrain.14 Interestingly, this exencephalic phenotype resembles that of animals with targeted mutations in other members of the mitochondrial death pathway such as APAF-1,15, 16 caspase-917 and caspase-3.18 p63-deficient mice, on the other hand, show grave developmental defects in limb and craniofacial formation and epithelial morphogenesis but do survive until a few days after birth.19, 20 p73 deficient mice exhibit a milder developmental phenotype, with defects specifically within the central nervous system (hippocampus) and the innate immune system. They survive to birth, but most p73-null mice die within 2 months after birth due to infection, with about 25% reaching adulthood.21 Aged p63+/− and p73+/− mice show a somewhat higher spontaneous tumor predisposition that is about half of the predisposition conferred by a p53+/−status.22
Defining the phenotype of compound disruptions in the gene family will be important. Mice with heterozygous compound null alleles of any two of the three family members reveal the cooperativity of family members in tumor suppression.22 However, homozygous compound double or even triple knockout mice have not been reported, possibly because they are difficult or even impossible to generate. Importantly, ΔNp73 acts as a dominant-negative pan inhibitor of p53, TAp73 and TAp63. Thus, we chose overexpression of ΔNp73 as an alternate way to create functional compound knockout animals of the p53 gene family. We, therefore, set out to generate mice overexpressing the α variant of human ΔNp73. Initially, we used constitutive overexpression of Flag-tagged ΔNp73α driven by a CMV promoter. As negative control, mice expressing an inactive (tetramerization-incompetent but DNA-binding competent) mutant form of ΔNp73α (L322P) were also created (Figure 1a).5, 11 These constructs were first verified for protein expression in the p53-null human cancer cell line H1299. As shown in Figure 1b, a clear Flag signal was obtained from cells transfected with wild-type and mutant ΔNp73 constructs, but not from cells transfected with green fluorescent protein (GFP).
We then microinjected the CMV-based wild-type ΔNp73 construct into zygotes obtained from superovulated, mated C57Bl/6 mice and implanted them into pseudo-pregnant isogenic mice in an attempt to create ΔNp73 α transgenic mice. However, we could never obtain transgenic litters. We, therefore, repeated the injections and collected embryos at stage E8.5, characterizing them for transgenesis by genomic PCR and phenotypic survival (Figure 1c). Implantation of zygotes injected with the wild-type ΔNp73α construct resulted in 14 successful implantations. However, by day E8.5, four implantation sites showed complete resorption of their embryos. Moreover, of the 10 remaining viable embryos, only three were normal. The other seven embryos were abnormal: three had begun to resorb, while four were small and developmentally delayed (E6.5–E8.0). Of these seven abnormal embryos, six were shown by PCR to contain the ΔNp73α transgene (Figure 1c). In contrast, implantation of zygotes injected with the mutant ΔNp73α (L322P) construct resulted in 26 successful implantation sites, all of which contained viable embryos at day 8.5. Only one of these embryos showed phenotypic abnormality, and 15 embryos were shown by PCR to carry the mutant ΔNp73α L322P transgene (Figure 1c). Taken together, we conclude that forced overexpression of wild-type ΔNp73α, but not the L322P mutant, in developing mice is embryonically lethal. We, therefore, attempted to switch to an inducible expression system.
We generated a new set of ΔNp73α transgenics in the tet-inducible expression vector pTRE2 (Tet-On, Clontech) (Figure 2a). The TRE promoter is designed to be inactive in the absence of a tetracycline-sensitive transactivator and tetracycline. We first verified the inducible expression of ΔNp73α through transient and stable transfections into HeLa cells stably transfected with the tet-inducible transactivator (Clontech) (Figure 2b). Addition of doxycycline to ΔNp73α -transfected but not to empty vector-transfected cells resulted in abundant ΔNp73α protein expression, indicating that this construct was readily tet-inducible. However, we also reproducibly detected low levels of ΔNp73α protein expression in stably transfected cells in the absence of doxycycline, indicating that tetracycline regulation of transgene expression was leaky.
Since leaky expression was relatively low, we proceeded with pronuclear injections with this construct in an attempt to create tet-inducible ΔNp73α transgenic mice. However, we encountered an abnormally low success rate (expected to be 30–40%). Only one out of 63 mice generated from these injections contained the transgene (1.5%), as detected by genomic PCR and Southern blotting. This founder was mated with a mouse transgenic for the tetracycline-sensitive transactivator23 and the transgene was found to be inherited in a Mendelian ratio. However, when RNA samples from the resulting double heterozygous pups were analyzed, we were unable to detect expression of the transgene, either before or after adding doxycycline to the drinking water of the pups (data not shown). We assumed that the TRE ΔNp73α transgene was also leaky in vivo, causing all animals with transgene expression to die in utero. The single transgenic founder we obtained survived because the transgene had integrated into a transcriptionally silent locus of the genome.
To test this possibility directly, we injected more pronuclei with our tet-inducible ΔNp73α construct and harvested the resulting embryos at days E8.5, E9.5 and E10.5. In our hands, micromanipulation of mouse zygotes in general, involving injection of the embryos with a transgene and transfer of injected embryos into a foster mother, normally yields a 30–40% transgenic birth rate. Here, we also found that wild-type embryos consistently showed a 30–40% survival rate at E10.5 (Figure 2c, d). However, as predicted, we found that the survival rate for ΔNp73α transgenic embryos dropped to 0% from E8.5 to E10.5 (Figure 2c, d). At day E8.5, we obtained only viable embryos (23 in total) and saw no evidence of resorption. In all, 15 of those embryos (65%) were shown by PCR to contain the transgene (data not shown). At day E9.5, we obtained 13 viable embryos and 10 empty uterine sacs, indicating that 10 of 23 embryos had died and undergone resorption. Only four out of the 13 viable embryos (31%) contained the transgene. At day E10.5, we detected only four viable wild-type embryos and 10 additional implantation sites containing resorbing transgenic embryos in the transgenic litter. The kinetics of loss of embryonic viability indicates that ΔNp73α transgenics are unable to develop past E9.5. Importantly, forced overexpression of the inactive mutant ΔNp73α (L322P) allele in transgenic animals did not lead to embryonic death (Figure 1c), indicating that this embryonic lethality is specific for wild-type ΔNp73α protein expression. To prove that the lethal phenotype of these transgenic embryos was in fact due to leaky expression of ΔNp73α protein, we repeated these experiments and assayed for transgene expression in day E8.5 embryos, using Flag immunoblotting of whole embryo extracts (Figure 2e). From a litter of seven embryos, three were nontransgenic and phenotypically normal. Of the remaining four, which were all transgenic, one had died and three were phenotypically abnormal. Of note, the three abnormal but still viable embryos also expressed the transgenic ΔNp73α protein (Figure 2e).
To further support the hypothesis that ΔNp73 might function as a potent pan inhibitor of the p53 gene family in development, we undertook a histological and functional characterization of ΔNp73α transgenic embryos. At E7.5, wild-type embryos had undergone gastrulation, generating an amnionic membrane and chorionic ectoderm (Figure 2f top left). In contrast, ΔNp73α transgenic embryos lacked these developmental landmarks and instead resembled E6–6.5 embryos (Figure 2f, top right). Thus, transgenic embryos are histologically abnormal. Combined with loss of viability past E9.0–9.5 (Figure 2d), this suggests that they fail at gastrulation and subsequently die.
A pronounced p53-dependent apoptotic response in E6.5–E7.5 embryos in utero, which is our window of interest, can be triggered by γIR of pregnant mice (6 h after 1.5 Gy).24 This apoptosis is not observed in p53−/− mice.24 On the other hand, it is essential for survival of wild-type mice, since no p53 −/− mice are born that have been subjected to this dose of radiation.24 Therefore, we compared wild-type and transgenic embryos under this condition. As anticipated, wild-type embryos irradiated in utero with 1.5 Gy showed a robust apoptotic response limited to the embryonic tissue. In contrast, transgenic embryos either completely lacked this response or showed only a remnant activity compared to wild-type (representative embryos in Figure 2f compare left and right TUNEL panels).
Our finding of embryonic lethality by deregulated ΔNp73α expression, a potent pan-dominant negative inhibitor of p53, TAp73 and most likely of TAp63, is significant, considering that single gene deficiencies of neither p53, p63 and p73 cause embryonic lethality. We know that both p53 and p73 play an important role in neuronal differentiation through apoptotic regulation of neuronal growth. Thus, we expected exogenous overexpression of ΔNp73 to specifically deregulate neuronal differentiation. However, our results from this study clearly show that deregulated expression of ΔNp73 during embryogenesis completely disables development earlier than day E8.5–E9.5, prior to the neurogenesis of the central nervous system. In summary, deregulated expression of the dominant negative pan p53/TA63/TA73 inhibitor ΔNp73α causes an earlier and, therefore, broader disruption of development than even the most severe single gene deficiency of the p53 family, that is, that of p63. Thus, this data demonstrates that the gene family members have distinct nonoverlapping functions in development, confirming earlier conclusions from single gene knockout studies, but interestingly, whose combined action appears to be more than the sum of its parts. Moreover, since homozygous compound double or even triple knockout animals have not yet been reported, our study shows that the p53 gene family as a whole is an upstream survival/death checkpoint that functions as an essential rheostat in early embryonic development.
References
Kaghad M et al. (1997) Cell 90: 809–819
Flores ER et al. (2002) Nature 416: 560–564
De Laurenzi VD et al. (1999) Cell Death Differ. 6389–6390
Concin N et al. (2004) Cancer Res. 64: 2449–2460
Zaika AI et al. (2002) J. Exp. Med. 196: 765–780
Stiewe T et al. (2002) Cancer Res. 62: 3598–3602
Uramoto H et al. (2004) Clin. Cancer Res. 10: 6905–6911
Tomkova K et al. (2004) Cancer Res. 64: 6390–6393
Frasca F et al. (2003) Cancer Res. 63: 5829–5837
Casciano I et al. (2002) Cell Death Differ. 9: 246–251
Petrenko O, Zaika A and Moll UM (2003) Mol. Cell. Biol. 23: 5540–5555
.Pozniak CD et al. (2000) Science 289: 304–306
Donehower LA et al. (1992) Nature 356: 215–221
Sah VP et al. (1995) Nat. Genet. 10: 175–180
Cecconi F et al. (1998) Cell 94: 727–737
Yoshida H et al. (1998) Cell 94: 739–750
Kuida K et al. (1998) Cell 94: 325–337
Kuida K et al. (1996) Nature 384: 368–372
Yang A et al. (1999) Nature 398: 714–718
Mills AA et al. (1999) Nature 398: 708–713
Yang A et al. (2000) Nature 404: 99–103
Flores ER et al. (2005) Cancer Cell 7: 363–373
Hsu W, Shakya R and Constantini F (2001) J. Cell Biol. 155: 1055–1064
Heyer BS et al. (2000) Genes Dev. 14: 2072–2084
Gossen M and Bujard H (1992) Proc. Natl. Acad. Sci. USA 89: 5547–5551
Meyer-Ficca ML et al. (2004) Anal. Biochem. 334: 9–19
Acknowledgements
This work was supported by Grant CA9385304 from the National Cancer Institute to UMM.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Erster, S., Palacios, G., Rosenquist, T. et al. Deregulated expression of ΔNp73α causes early embryonic lethality. Cell Death Differ 13, 170–173 (2006). https://doi.org/10.1038/sj.cdd.4401743
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4401743